Cell-derived xenograft (CDX) model is a well-recognized and commonly used model for research and development of anti-tumor drugs. The CDX model is also widely used in the early stage of in vivo study due to its user-friendly technology and excellent repeatability. CDX model is established by inoculating long-term, in vitro passaged tumor cells into immunodeficient mice. As an indispensable step in the discovery process of tumor drugs, CDX model offers key decision-making information to allow agents to move forward, and clients to advance their preclinical development programs in a timely and cost-effective manner.
Creative Bioarray has a list of more than 90 tumor cell lines that can be used in immunocompromised mice. Stocks of tumor cells are well defined and obtained only from trusted sources. We can also provide subcutaneous, orthotopic, or metastatic tumor models according to the customer's requirements, as well as in vivo pharmacological and pharmacodynamic services for the corresponding models.
Standard in vivo models are available for the following cell lines:
|Tumor Type||Cell Line|
|Brain cancer||LN229, SF268, SF295, SF539, SK-N-AS, SNB-19, SNB-75, U-251 MG, U87 MG|
|Breast cancer||BT474, BT-549, HS578T, KPL-4, MCF-7, MDA-MB-157, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D|
|Colon cancer||COLO-205, CT-26, DLD-1, HCT116, HCT-15, HT-29, KM-12, L0Vo, LS-174T, MC38, RKO, SW480, SW-620, WiDr|
|Gastric cancer||AGS, HS746T, MKN-45, NCI-N87, SNU-16, SGC-7901|
|Hepatocellular cancer||Hepa1-6, Hep3B, HepG2, SK-HEP-1, SMMC-7721|
|Kidney cancer||786-O, A498, Caki-1, HEK-293, Renca|
|Leukemia/Lymphoma||A20, DOHH2, EL-4, HL-60, K-562, Karpas-299, MOLM-13, Ramos, Raji|
|Lung cancer||A549, Calu-3, Calu-6, H1155, Huh7, NCI-H226, NCI-H460, NCI-H1975|
|Melanoma||A375, A2058, SK-MEL-2|
|Ovarian cancer||OV-CAR3, SKOV-3|
|Pancreatic cancer||AsPC-1, BxPc-3, MIAPaCa-2, PANC-1|
|Prostate cancer||DU-145, LNCaP, MDA-PCA2b, PC-3|